Page 2 - Eric Kelsic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MedCity News Andreessen Horowitz leads $100M Series A round in Dyno and its gene therapy tech Dyno Therapeutics’ technology for designing viral vectors that deliver gene therapies has led to partnerships with Novartis, Sarepta Therapeutics, and Roche. With the Series A financing, the startup plans to expand its technology to address more tissue types, and potentially add more partners. Shares0 Improved AAV vector capsid for gene therapy engineered with a new machine-guided approach shows, in red, improvements in efficiency of viral production based on the average effect of insertions at a...

Dyno raises $100 million to bring artificial intelligence to gene therapy By Anissa Gardizy Globe Staff,Updated May 6, 2021, 11:21 a.m. Email to a Friend Dyno Therapeutics chief executive Eric Kelsic.Courtesy of Dyno Therapeutics Dyno Therapeutics, a Cambridge biotech that uses artificial intelligence to develop gene therapies, said Thursday that it has raised $100 million from investors. The company uses machine learning to design a type of gene therapy “vector” — or carrier — aiming to make treatments that are easier to deliver and more effective. Dyno said the funding...

 E-Mail IMAGE: In their machine learning-based capsid diversification strategy, the team focused on a 28 amino acid peptide within a segment of the AAV2 VP3 capsid protein that exposes the AAV capsid... view more  Credit: Wyss Institute at Harvard University (original by Drew Bryant) (Boston) -- Adeno-associated viruses (AAVs) have become promising vehicles for delivering gene therapies to defective tissues in the human body because they are non-pathogenic and can transfer therapeutic DNA into target cells. However, while the first gene therapy products approved by the Federal Drug Ad...